This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

It has a strong antipyretic effect on rabbits with fever caused by bacterial endotoxins; it can counteract the increased permeability of capillary walls caused by xylene or histamine; it has a significant sedative effect; it can promote the adrenal cortex function of rats and enhance the body's emergency response to pathogen infection; it has a certain inactivation effect on influenza virus type A1, type A3, pneumonia adenovirus (Adv) type III, type IV, enterosyncytial virus and respiratory syncytial virus (RSV) in vitro.

The specific pharmacological effects are not clear from the above information. Please refer to the detailed drug instructions.

This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, it can promote the outflow of K in myocardial cells, reduce the autonomy of the myocardium, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of the heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.

It selectively excites the medullary respiratory center and can also act on the carotid body and aortic body chemoreceptors to reflexively excite the respiratory center and increase the respiratory center's sensitivity to carbon dioxide, deepening and accelerating breathing. It has a weak excitatory effect on the vasomotor center. Excessive doses can cause convulsions.